<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">ESMOLOL HYDROCHLORIDE</span><br/>(ess'moe-lol)<br/><span class="topboxtradename">Brevibloc<br/></span><b>Classifications:</b> <span class="classification">autonomic nervous system agent</span>; <span class="classification">beta-adrenergic antagonist (blocking agent, sympatholytic)</span><br/><b>Prototype: </b>Propranolol<br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>10 mg/mL, 250 mg/mL injection</p>
<h1><a name="action">Actions</a></h1>
<p>Ultrashort-acting beta<sub>1</sub>-adrenergic blocking agent with cardioselective properties but devoid of intrinsic sympathetic activity (ISA) or membrane-stabilizing
         (quinidine-like) activity. Hemodynamic effects are mild, with potency as a beta blocker about 1/100 that of propranolol. Inhibits
         the agonist effect of catecholamines by competitive binding at beta-adrenergic receptors.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Blocks sympathetically mediated increases in cardiac rate and BP since it binds predominantly to beta<sub>1</sub>-receptors in cardiac tissue.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Supraventricular tachyarrhythmias (SVT) in perioperative and postoperative periods or in other critical situations. Also short-term
         treatment of noncompensating sinus tachycardia and in the control of heart rate for patients with MI.
      </p>
<h1><a name="unlabeleduses">Unlabeled Uses</a></h1>
<p>Moderate postoperative hypertension; treatment of intense transient adrenergic response to surgical stress in cardiac as well
         as noncardiac surgery.
      </p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Cardiac failure, heart block greater than first degree, sinus bradycardia, cardiogenic shock; pregnancy (category C), lactation.
         Safety in children is not established.
      </p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>History of allergy or bronchial asthma, bronchospasm, emphysema; CHF; diabetes mellitus; kidney function impairment.</p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Supraventricular Tachyarrhythmias</span><br/><span class="rdage">Adult:</span> <span class="rdroute">IV</span> 500 mcg/kg loading dose followed by 50 mcg/kg/min, may increase dose q510min prn (max: 200 mcg/kg/min)<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1>
<ul>
<li>
            				Note: Do not use the 2500 mg ampul for direct IV injection.
            			
         </li>
</ul>
<table cellpadding="4" cellspacing="0" class="ivbox" width="100%">
<tr>
<td><span class="ivtitle">Intravenous</span><p><span class="routemethod">PREPARE:</span> <span class="methodtype">Direct:</span> Use the 10 mg/mL vial undiluted for the loading dose.  <span class="methodtype">IV Infusion:</span> Prepare maintenance infusion by adding 250 mL of diluent to each 2500 mg ampul to yield 10 mg/mL. Compatible diluents include
                  D5W, D5/RL, D5/NS, D5/.45NS, RL.  
               </p>
<p><span class="routemethod">ADMINISTER:</span> <span class="methodtype">Direct:</span> Give loading dose over 1 min.  <span class="methodtype">IV Infusion:</span> Give maintenance infusion over 4 min. If adequate response is noted, continue maintenance infusion with periodic adjustments
                  as needed. If an adequate response has not occurred, repeat loading dose and follow with an increased maintenance infusion
                  of 100 mcg/kg/min. May continue titration cycle with same loading dose while increasing maintenance infusion by 50 mcg/kg/min
                  until desired end point is near. Then omit loading dose and titrate maintenance dose up or down by 25 to 50 mcg/kg/min until
                  desired heart rate is reached.  
               </p>
<p><span class="routemethod">INCOMPATIBILITIES</span> <span class="incompattype">Solution/Additive:</span>
<b> Procainamide.</b>
<span class="incompattype">Y-site:</span>
<b>Amphotericin B cholesteryl,</b>
<b>furosemide,</b>
<b>warfarin.</b>
</p>
</td>
</tr>
</table>
<ul>
<li>Diluted infusion solution is stable for at least 24 h at room temperature.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">CNS:</span> Headache, <span class="speceff-common">dizziness,</span> somnolence, confusion, agitation. <span class="typehead">CV:</span>
<span class="speceff-common">Hypotension</span> (dose related), cold hands and feet, bradyarrhythmias, flushing, myocardial depression. <span class="typehead">GI:</span> Nausea, vomiting. <span class="typehead"> Respiratory:</span> Dyspnea, chest pain, rhonchi, <span class="speceff-life">bronchospasm</span>. <span class="typehead">Skin:</span>
<span class="speceff-common">Infusion site inflammation</span> (redness, swelling, induration). 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> May increase <b>digoxin</b> IV levels 1020%; <b>morphine</b> IV may increase esmolol levels by 45%; <b>succinylcholine</b> may prolong neuromuscular blockade. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead"> Onset:</span>  Peak: 1020 min. <span class="typehead">Duration:</span> 1030 min. <span class="typehead">Metabolism:</span> Rapidly hydrolyzed by RBC esterases. <span class="typehead">Elimination:</span> Eliminated in urine. <span class="typehead">Half-Life:</span> 9 min. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor BP, pulse, ECG, during esmolol infusion. Hypotension may have its onset during the initial titration phase; thereafter
            the risk increases with increasing doses. Usually the hypotension experienced during esmolol infusion is resolved within 30
            min after infusion is reduced or discontinued.
         </li>
<li>Change injection site if local reaction occurs. IV site reactions (burning, erythema) or diaphoresis may develop during infusion.
            Both reactions are temporary. Blood chemistry abnormalities have not been reported.
         </li>
<li>Overdose symptoms: Discontinue administration if the following symptoms occur: bradycardia, severe dizziness or drowsiness,
            dyspnea, bluish-colored fingernails or palms of hands, seizures.
         </li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>